PhRMA cries foul on CMS' registry approach for Alzheimer's disease drugs

As Biogen and Eisai’s second Alzheimer’s drug Leqembi nears a potential full FDA approval, the Centers for Medicare and Medicaid Services (CMS) this week detailed plans to cover new Alzheimer’s meds with the use of a registry to collect real-world data. But industry trade group PhRMA has problems with the approach.